CYRX PE Ratio & Valuation, Is CYRX Overvalued
This article analyzes the valuation of Cryoport Inc (CYRX), deeming it to be in the "Fair zone" with a fair price range between $4.45 and $28.16 according to relative valuation methods. It highlights that the current forward PS ratio of 2.09 is considered fair compared to its five-year average. The analysis also notes that CYRX's P/S ratio is significantly above the industry average, suggesting that its premium may be unsustainable despite robust revenue growth.
CryoPort (CYRX): New Buy Rating Initiated with $15 Price Target
Craig-Hallum has initiated coverage on CryoPort (CYRX) with a 'Buy' rating and a new price target of $15.00, reflecting analyst Matthew Hewitt's optimism for the company's future. This new rating adds to a history of positive analyst attention for CryoPort, which specializes in temperature-controlled supply chain solutions for the life sciences industry. Wall Street analysts currently project an average target price of $13.33 for CYRX, with an "Outperform" consensus rating.
Craig-Hallum initiates coverage of Cryoport (CYRX) with buy recommendation
Craig-Hallum has initiated coverage of Cryoport (CYRX) with a buy recommendation. This suggests a positive outlook on the company's stock from the investment banking firm.
Craig Hallum Initiates Coverage on CryoPort (NASDAQ:CYRX)
Craig Hallum has initiated coverage on CryoPort (NASDAQ:CYRX) with a "Buy" rating and a $15.00 price target, suggesting an 87% upside. This follows CryoPort's recent financial results, which missed EPS but beat revenue estimates, and mixed analyst ratings including downgrades and price target increases from other firms. Insider selling has occurred recently, though institutional ownership remains high at 92.90%.
Craig-Hallum initiates coverage of Cryoport (CYRX) with buy recommendation
Craig-Hallum has initiated coverage of Cryoport (CYRX) with a buy recommendation. This signals a positive outlook from the investment firm regarding the company's stock performance.
Vanguard disaggregates holdings; CYRX shows 0 shares after realignment (CYRX)
The Vanguard Group has reported 0 beneficially owned shares of CryoPort Inc (CYRX) common stock in an amended Schedule 13G/A filing. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries now report their holdings separately, in accordance with SEC Release No. 34-39538. The filing clarifies a reporting structure change rather than indicating any sales or purchases by Vanguard of CryoPort stock.
CYRX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Cryoport Inc (CYRX), focusing on its revenue breakdown, profitability margins, and a comparison with competitors. The company generates most of its revenue from Life Science products, and while it boasts a strong gross margin, its operating and net margins are negative. The analysis also benchmarks CYRX's performance against industry peers like RLGT and FLX.
Cryoport CYRX CFO Stefanovich sells $8948 in shares
Cryoport (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,094 shares of common stock for $8,948 on March 23, 2026. This transaction was primarily to cover taxes related to vesting restricted stock rights. Despite the sale, Stefanovich still directly owns a significant number of shares, and the company recently reported mixed Q4 2025 earnings with revenue beating expectations but EPS falling short.
Tax-driven share sale by Cryoport (NASDAQ: CYRX) CFO after vesting
Cryoport, Inc.'s CFO, Robert Stefanovich, reported a tax-related sale of 1,094 shares of common stock at $8.18 per share. This sale was a mandatory withholding event under company policy to cover taxes due upon the vesting of restricted stock rights, not a discretionary reduction of his stake. Following this transaction, Stefanovich directly holds 279,277 shares, indicating a routine compensation-related event.
Cryoport (CYRX) CEO exercises 25,000 options, sells shares for taxes
Cryoport, Inc.'s President and CEO, Jerrell Shelton, recently exercised options to acquire 25,000 shares of common stock at $1.87 per share. Concurrently, he sold 2,894 shares at $8.18 each to cover tax obligations related to vested restricted stock rights, as dictated by company policy. Following these transactions, Shelton directly holds 1,076,607 shares, indicating the sale was routine and tax-driven rather than a discretionary reduction in his investment.
Cryoport (CYRX) CSO executes 1,341-share tax-related sale after RSU vesting
Cryoport, Inc.'s Chief Scientific Officer, Mark W. Sawicki, reported an automatic sale of 1,341 shares of common stock at $8.18 per share. This sale was conducted to cover tax obligations incurred from the vesting of restricted stock rights, as mandated by company policy. Following this transaction, Sawicki directly retains ownership of 102,356 shares of Cryoport common stock.
Cryoport CYRX CFO Stefanovich sells $8948 in shares
Cryoport Inc. (NASDAQ: CYRX) Chief Financial Officer Robert Stefanovich sold 1,094 shares of common stock for $8,948 to cover taxes related to restricted stock vesting. Following this transaction, Stefanovich directly owns 279,277 shares. The company recently reported mixed Q4 2025 earnings, with revenue exceeding expectations but EPS falling short.
CryoPort (NASDAQ:CYRX) Insider Sells $10,969.38 in Stock
CryoPort (NASDAQ:CYRX) insider Mark Sawicki sold 1,341 shares of company stock for $10,969.38 on March 23, reducing his ownership by 1.29%. Following the sale, he now owns 102,356 shares valued at approximately $837,272.08. The company's shares traded up 3.2% at $8.41, with a market cap of $419.32 million, and analysts have a "Moderate Buy" rating with a consensus target price of $12.94.
CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of "Moderate Buy" from Brokerages
CryoPort, Inc. (NASDAQ:CYRX) has an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $12.94 despite recent insider selling and an EPS miss. Insiders sold over 54,000 shares in the last three months, though major institutional investors have increased their holdings. The company's stock currently trades around $8.04, with a market capitalization of $400.87 million, and specializes in temperature-controlled logistics for the life sciences industry.
CryoPort, Inc. (CYRX) Just Flashed Golden Cross Signal: Do You Buy?
This article discusses CryoPort, Inc. (CYRX) and the "golden cross" signal its stock recently flashed. It prompts readers to consider if this technical indicator suggests a good buying opportunity. The analysis likely delves into what a golden cross signifies and its potential implications for CYRX's stock performance.
Cryoport, Inc. (NASDAQ:CYRX) Q4 2025 earnings call transcript
This document is a transcript of the Q4 2025 earnings call for Cryoport, Inc. (NASDAQ:CYRX). It details the financial results and discussions from the company's fourth fiscal quarter of 2025.
Cryoport (CYRX) CEO Shelton sells $63k in shares
Cryoport (CYRX) CEO Jerrell Shelton sold 7,918 shares of common stock for $63,344 to cover taxes on restricted stock, according to a recent SEC filing. This transaction occurred on March 16, 2026, and leaves Shelton with 1,054,501 directly owned shares. The company recently reported a Q4 2025 revenue beat, but an earnings per share miss, indicating mixed financial performance.
Cryoport’s (CYRX) Zecchini sells $16k in shares
Edward J. Zecchini, Chief Digital and Technology Officer at Cryoport, Inc. (CYRX), sold 2,014 shares of company stock for $16,112 on March 16, 2026. This transaction occurred after Zecchini acquired 21,322 restricted stock rights and was granted 63,965 stock options on March 14, 2026. Following these transactions, Zecchini directly owns 109,719 Cryoport shares, while the company recently reported mixed Q4 2025 results with a revenue beat but an EPS miss.
Cryoport CEO eyes strong 2026 but Iran war, FDA leadership pose risks
Cryoport, a Nashville-based public health care company, anticipates a strong year in 2026. CEO Jerrell Shelton has outlined factors that could influence this momentum, including potential risks like the Iran war and challenges related to FDA leadership. The company is preparing for these potential impacts while looking forward to what the year holds.
CryoPort (NASDAQ:CYRX) Insider Mark Sawicki Sells 3,235 Shares
Mark Sawicki, an insider at CryoPort (NASDAQ:CYRX), sold 3,235 shares of the company's stock on March 16th, 2026, for a total of $25,880, reducing his stake by 3.03%. This transaction follows CryoPort's recent quarterly earnings report where the company missed EPS estimates but exceeded revenue expectations. Analyst ratings for CYRX are mixed, with a "Moderate Buy" consensus and an average target price of $12.94.
CryoPort (NASDAQ:CYRX) Insider Edward Zecchini Sells 2,014 Shares
CryoPort (NASDAQ:CYRX) insider Edward Zecchini sold 2,014 shares of the company's stock on March 16th at an average price of $8.00, reducing his ownership by 1.8%. The company recently reported quarterly earnings missing EPS estimates but exceeding revenue expectations. Analysts generally rate CryoPort as a "Moderate Buy" with an average price target of $12.94, and institutional investors hold a significant portion of its shares.
Jerrell Shelton Sells 7,918 Shares of CryoPort (NASDAQ:CYRX) Stock
Jerrell Shelton, CEO of CryoPort (NASDAQ:CYRX), sold 7,918 shares of the company's stock for $63,344 on March 16, reducing his stake by 0.75%. The sale comes as CryoPort missed earnings per share estimates but beat revenue expectations for the last quarter. Institutional investors hold a significant portion of the stock, and Wall Street analysts currently rate it a "Moderate Buy" with a consensus price target of $12.94.
Equity grants and tax-related sale by Cryoport (CYRX) officer Zecchini
Cryoport, Inc. officer Edward J. Zecchini reported receiving 21,322 restricted stock rights and a stock option grant for 63,965 shares. He also sold 2,014 shares of Common Stock to cover tax obligations related to the vesting of restricted stock rights. Following these transactions, Zecchini directly holds 109,719 shares of Common Stock.
Cryoport (NASDAQ: CYRX) CEO granted 492,901 options, sells 7,918 shares for taxes
Cryoport, Inc.'s CEO, Jerrell Shelton, reported two significant transactions: the sale of 7,918 shares of common stock at $8.00 per share to cover taxes on vested restricted stock, and the grant of 492,901 stock options with an exercise price of $8.60, vesting over 48 months. After the sale, Shelton directly owns 1,054,501 common shares. The stock options are a long-term incentive, expiring in 2033, and vest monthly starting April 14, 2026.
Cryoport (CYRX) CSO granted stock awards and executes tax-related sale
Cryoport, Inc.'s Chief Scientific Officer, Mark W. Sawicki, received 22,845 restricted stock rights and stock options for 68,534 shares. He also conducted a tax-related sale of 3,235 common shares at $8.00 each to cover vesting taxes. Following these transactions, Sawicki directly holds 103,697 shares of Cryoport common stock, in addition to the newly granted stock options.
Mak Capital One LLC Acquires New Position in CryoPort, Inc. $CYRX
Mak Capital One LLC has acquired a new stake of 818,162 shares in CryoPort, Inc. (NASDAQ:CYRX) during Q3, totaling approximately $7.76 million, making it their 11th-largest position. This represents about 1.63% ownership of the company. Despite a slight EPS miss, CryoPort recorded a revenue beat at $45.45 million, and analysts currently rate the stock as a "Moderate Buy" with a target price of $12.94.
Fred Alger Management LLC Has $16.88 Million Position in CryoPort, Inc. $CYRX
Fred Alger Management LLC reduced its stake in CryoPort, Inc. by 24.5% during the third quarter, holding 1,780,495 shares valued at $16.88 million. Despite this, institutional investors and hedge funds collectively own 92.90% of the company's stock. CryoPort recently missed quarterly EPS estimates but exceeded revenue expectations, and analysts currently have a "Moderate Buy" rating with a consensus target price of $12.94.
CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 2,743 Shares
CryoPort's CFO, Robert Stefanovich, recently sold 2,743 shares of the company's stock for $8.00 per share, totaling $21,944, reducing his holdings by 0.97%. This follows a previous sale of 38,700 shares on March 12th. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with a target price of $12.94.
Cryoport CFO Stefanovich sells $322k in shares
Cryoport's CFO, Robert Stefanovich, sold 41,443 shares of common stock in two transactions in March 2026, totaling approximately $322,329, while also exercising options and acquiring restricted stock rights. This comes after Cryoport (NASDAQ:CYRX) reported mixed Q4 2025 earnings, beating revenue expectations but missing on EPS, causing a decline in aftermarket trading due to stock price volatility.
Cryoport Inc Stock (ISIN: US2289031005) Faces Investor Pressure Amid Stake Reductions
Thematics Asset Management has reduced its stake in Cryoport Inc by 14.4%, signaling increased investor caution in the biopharma logistics sector. This move comes as the company navigates broader market dynamics and potential headwinds from slower biopharma funding. Despite this, Cryoport's core business model in temperature-controlled supply chain solutions for advanced therapies, supported by high institutional ownership and a strong balance sheet, suggests long-term growth potential for patient investors.
Trading Systems Reacting to (CYRX) Volatility
The article analyzes Cryoport Inc. (NASDAQ: CYRX), indicating weak near and mid-term sentiment, although the long-term outlook remains positive. It highlights potential downside risk due to a lack of additional long-term support signals and provides three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.
Thematics Asset Management Lowers Holdings in CryoPort, Inc. $CYRX
Thematics Asset Management reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by 14.4% in the third quarter, while other institutional investors like UBS Group AG, Assenagon Asset Management S.A., Kennedy Capital Management LLC, Norges Bank, and AQR Capital Management LLC increased or opened new positions. CryoPort's stock opened at $7.82, with a market capitalization of approximately $389.91 million and a P/E ratio of 5.92. Analysts have a "Moderate Buy" rating for the company with an average target price of $12.94, despite missing quarterly EPS estimates but exceeding revenue expectations.
CYRX Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to Cryoport (CYRX) stock, including financial results and product announcements. Key highlights include Cryoport exceeding 2025 revenue guidance, reporting strong Q4 2025 revenue, and launching new cryogenic storage technologies. The company also provided positive revenue guidance for FY26.
Cryoport, Inc. (NASDAQ:CYRX) Q4 2025 earnings call transcript
This is an earnings call transcript for Cryoport, Inc. (NASDAQ:CYRX) for the fourth quarter of 2025. The transcript details the company's financial results and discussions with analysts regarding its performance.
CryoPort (NASDAQ:CYRX) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen has downgraded CryoPort (NASDAQ:CYRX) from a "hold" to a "sell" rating, though the general analyst consensus remains a "Moderate Buy" with a $12.94 average price target. This downgrade follows an EPS miss for the quarter despite revenue exceeding estimates, causing a 3.2% drop in shares. The article also notes significant institutional ownership and a recent insider stock sale.
Cryoport (CYRX) Q4 Loss Of US$0.21 Per Share Tests Bullish Margin Narratives
Cryoport (CYRX) reported a Q4 FY 2025 loss of US$0.21 per share and US$45.5 million in revenue, highlighting consistent top-line scale but ongoing bottom-line pressure. While the company has narrowed losses over five years and supports a significant portion of cell and gene clinical trials, the path to profitability remains a work in progress. Critics note that the stock price of US$8.74 is significantly higher than its DCF fair value of US$1.70, suggesting over-optimism despite modest 7.9% revenue growth and persistent losses.
Cryoport 10-K: Revenue $176.2M, Net Income $78.3M
Cryoport (CYRX) reported fiscal results from its 10-K filing, showing total revenue of $176.2 million, a 12.4% year-over-year increase, and a net income of $78.3 million. This significant net income was largely driven by a $117.0 million gain from a strategic divestiture of CRYOPDP, which allowed the company to refocus on its core temperature-controlled services. The company also improved its loss from continuing operations and expanded gross margins, reflecting stronger demand in BioLogistics and BioStorage services and increased operational efficiency, particularly in the cell and gene therapy market.
Cryoport Inc earnings missed by $0.06, revenue topped estimates
Cryoport Inc (CYRX) reported first-quarter EPS of $-0.27, missing analyst estimates by $0.06, despite revenue of $45.45 million exceeding the consensus estimate of $42.93 million. The company provided a FY 2026 revenue guidance of $190.00M-$194.00M, which is above the analyst consensus. Cryoport Inc's stock has fallen -11.01% in the last three months but is up 67.79% over the last 12 months.
Cryoport, Inc. (NASDAQ:CYRX) Q4 2025 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX) reported its Q4 and full-year 2025 earnings, exceeding revenue guidance with $176.2 million from continuing operations. The company saw significant growth in commercial cell and gene therapy revenue, which increased 29% year-over-year, and expanded its clinical trial support. Despite missing EPS expectations, Cryoport anticipates achieving positive adjusted EBITDA in the second half of 2026 and expects continued momentum in its life sciences segments, driven by commercial therapy approvals and strategic partnerships.
Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
This article compiles recent analyst rating changes and price target adjustments for ten different companies, including Semtech, Saia, MARA Holdings, CryoPort, Figs, Gitlab, Theravance Biopharma, Vir Biotechnology, Crowdstrike Holdings, and Vulcan Materials. Semtech (SMTC) received an increased price target from Benchmark and maintains a Buy rating, suggesting a potential rally of around 28%. The report highlights a mix of upgrades, downgrades, and target revisions from various Wall Street firms for these companies.
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript Summary
Cryoport (CYRX) reported strong financial performance for Q4 and full year 2025, exceeding revenue guidance with significant growth in commercial cell and gene therapy. The company expanded its global infrastructure, launched innovative cryogenic freezers, and offered positive revenue guidance for 2026, anticipating positive adjusted EBITDA in the latter half of the year. Strategic collaborations and AI integration are expected to drive future growth despite a volatile macro environment.
Cryoport, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CYRX)
Cryoport, Inc. has published its slide deck in conjunction with its 2025 Q4 earnings call. The company reported an EPS of -$0.17, beating estimates by $0.04, and revenue of $45.45M, beating by $2.53M despite a 23.65% year-over-year decline. The presentation provides detailed insights into their performance.
CryoPort Inc. (CYRX) Stock Rises on Q4 2025 Earnings
CryoPort Inc. (CYRX) reported its Q4 2025 earnings, with revenue of $45.45 million, slightly above consensus, despite a 59.8% year-over-year decrease. The company posted a net loss of $13.64 million, or $0.27 diluted loss per share, missing analyst estimates. Following the announcement, the stock saw a modest rise of 1.31%.
How Cryoport Inc. (CYRX) Affects Rotational Strategy Timing
This article analyzes Cryoport Inc. (CYRX) for its impact on rotational strategy timing, highlighting divergent sentiment across different time horizons and suggesting choppy market conditions. It provides AI-generated institutional trading strategies for long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and offers real-time trading signals and personalized analysis with account creation.
CryoPort's Earnings Outlook
CryoPort (NASDAQ: CYRX) is expected to announce its quarterly earnings on March 3, 2026, with analysts estimating an EPS of $-0.20. Investors will be keen to see if the company beats this estimate and provides positive future guidance, as past earnings beats haven't always led to immediate stock price increases. The article also provides a financial overview, highlighting CryoPort's market capitalization, strong revenue growth, high net margin, and efficient asset utilization, while noting its lower reliance on debt.
Cryoport Inc expected to post a loss of 21 cents a share - Earnings Preview
Cryoport Inc (CYRX) is expected to announce an earnings loss of 21 cents per share. This information comes from a Refinitiv earnings preview. The article is a brief financial news update provided by Reuters.
CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
CryoPort, Inc. (NASDAQ:CYRX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $12.83. This comes despite a recent insider share sale by Director Ramkumar Mandalam. Institutional ownership in CryoPort is significantly high at 92.9%, demonstrating strong confidence from large investment firms.
CYRX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides an in-depth financial analysis of Cryoport Inc (CYRX), including its income statement, balance sheet, and cash flow statement, derived from SEC filings. The company's financial profile scores 41 out of 100, indicating moderate overall financial health based on profitability, growth, leverage, liquidity, cash flow, and returns. Key metrics highlight declining revenue, negative operating margins and net income, but also strong liquidity and conservative leverage.
CryoPort (CYRX) to Release Quarterly Earnings on Tuesday
CryoPort (NASDAQ:CYRX) is scheduled to release its Q4 2025 earnings after market close on Tuesday, March 3rd, with analysts anticipating a loss of ($0.19) per share and revenue of $42.9240 million. The company's stock has been trading down, with recent insider selling by a director. Institutional investors have also been active, while analysts have a "Moderate Buy" consensus rating with an average price target of $12.83.
(CYRX) and the Role of Price-Sensitive Allocations
Cryoport Inc. (NASDAQ: CYRX) is showing divergent sentiment across all horizons, suggesting choppy conditions with no clear price positioning signal and elevated downside risk. Stock Traders Daily's AI models have generated three distinct trading strategies: a Position Trading Strategy (LONG), a Momentum Breakout Strategy (BREAKOUT), and a Risk Hedging Strategy (SHORT), each with specific entry, target, and stop loss points. Multi-timeframe analysis indicates neutral near-term, weak mid-term, and strong long-term signals, with their AI-generated signals providing detailed support and resistance levels.
